
Liminatus Pharma fell 93.0% from $35.94 to $2.51, behind the S&P 500's +4.7%. Its worst day was Feb 11 (−52.6%), and its low came Nov 20 at $2.51.
Nov 21, 2025 – Nov 20, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Liminatus Pharma shares rose 41.3%, while the S&P 500 fell 0.3%.
+41.3% · S&P 500 −0.3%
Liminatus Pharma closed at its highest level of the year, 185.2% above where the year started.
+43.4% · S&P 500 −1.2%
Story events cover the past 12 months · Times ET
Gross proceeds, before deducting placement agent fees and other estimated offering expenses, are expected to be approximately $4.0 million.
−31.9% · S&P 500 +0.2%
Liminatus Pharma shares fell 31.1%, while the S&P 500 rose 0.4%.
−31.1% · S&P 500 +0.4%
Liminatus Pharma shares rose 29.0%, while the S&P 500 fell 0.5%.
+29.0%, on 12M shares, the year's heaviest volume · S&P 500 −0.5%
EPS of $-1.50 was reported on $0.00 revenue.
+1.0% · S&P 500 −0.5%
Where it ended: a close of $2.51 on Nov 20, 2026. Up next: Q3 2026 earnings on Dec 4, 2026.
Nothing in the past 12 months.
All LIMN analyst actionsNothing in the past 12 months.
All LIMN dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for LIMN and SPY from Benzinga historical bars. Not investment advice.